181 related articles for article (PubMed ID: 37620204)
1. Effectiveness of 13-valent pneumococcal conjugate vaccine on all-cause pneumonia in children under 5 years in Shanghai, China: An observational study.
Tian J; Zheng B; Yang L; Guan Y; Xu C; Wang W
Vaccine; 2023 Sep; 41(41):5979-5986. PubMed ID: 37620204
[TBL] [Abstract][Full Text] [Related]
2. Incidence and Estimated Vaccine Effectiveness Against Hospitalizations for All-Cause Pneumonia Among Older US Adults Who Were Vaccinated and Not Vaccinated With 13-Valent Pneumococcal Conjugate Vaccine.
Hsiao A; Hansen J; Timbol J; Lewis N; Isturiz R; Alexander-Parrish R; McLaughlin JM; Gessner BD; Klein NP
JAMA Netw Open; 2022 Mar; 5(3):e221111. PubMed ID: 35302634
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of 13-valent pneumococcal conjugate vaccine against community acquired pneumonia among children in China, an observational cohort study.
Zhang T; Zhang J; Shao X; Feng S; Xu X; Zheng B; Liu C; Dai Z; Jiang Q; Gessner BD; Chen Q; Zhu J; Luan L; Tian J; Zhao G
Vaccine; 2021 Jul; 39(33):4620-4627. PubMed ID: 34253417
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-serotype community acquired pneumococcal diseases among children in China: A test-negative case-control study.
Xiaofei L; Yudan LI; Qinghui C; Jiaming S; Benfeng Z; Youyi Z; Biying W; Lijun Y; Jun Z; Jianmei T; Lin L; Xuejun S; Genming Z; Tao Z
Vaccine; 2024 Feb; 42(6):1275-1282. PubMed ID: 38296700
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Medically Attended Lower Respiratory Tract Infection and Pneumonia Among Older Adults.
Lewnard JA; Bruxvoort KJ; Fischer H; Hong VX; Grant LR; Jódar L; Cané A; Gessner BD; Tartof SY
Clin Infect Dis; 2022 Sep; 75(5):832-841. PubMed ID: 34967907
[TBL] [Abstract][Full Text] [Related]
6. Protective effect of PCV13 against all-cause hospitalized pneumonia in children in Beijing, China: real-world evidence.
Lv M; Du J; Xie MZ; Zhou Y; Yang G; Wang J; Zhang WX; Yang H; Zhang SS; Cui F; Lu QB; Wu J
Vaccine; 2024 Apr; 42(12):3091-3098. PubMed ID: 38594120
[TBL] [Abstract][Full Text] [Related]
7. Pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Greece using urinary antigen detection tests: the EGNATIA study, November 2017 - April 2019.
Liapikou A; Konstantinidis A; Kossyvaki V; Skiadas J; Menegas D; Méndez C; Beavon R; Begier E; Gessner BD; Milionis H; Tsimihodimos V; Baxevanos G; Argiriadou T; Terrovitou C; Toumbis M;
Hum Vaccin Immunother; 2022 Nov; 18(5):2079923. PubMed ID: 35703733
[TBL] [Abstract][Full Text] [Related]
8. Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015-2016.
Vila-Corcoles A; Hospital I; Ochoa-Gondar O; Satue E; de Diego C; Vila-Rovira A; Gómez-Bertomeu F; Raga X; Aragón M
Vaccine; 2020 Jan; 38(5):1170-1180. PubMed ID: 31759735
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study in Japan.
Nakashima K; Suzuki K; Aoshima M; Murabata M; Kondo K; Ohfuji S; Fukushima W; Maeda A; Hirota Y;
Vaccine; 2022 Nov; 40(46):6589-6598. PubMed ID: 36184405
[TBL] [Abstract][Full Text] [Related]
10. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.
Shen K; Wasserman M; Liu D; Yang YH; Yang J; Guzauskas GF; Wang BCM; Hilton B; Farkouh R
PLoS One; 2018; 13(7):e0201245. PubMed ID: 30044865
[TBL] [Abstract][Full Text] [Related]
11. Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study.
Vila-Corcoles A; Ochoa-Gondar O; de Diego C; Satue E; Aragón M; Vila-Rovira A; Gomez-Bertomeu F; Magarolas R; Figuerola-Massana E; Raga X; Perez MO; Ballester F
BMC Infect Dis; 2018 Apr; 18(1):196. PubMed ID: 29699550
[TBL] [Abstract][Full Text] [Related]
12. High Prevalence of Vaccine-Type Infections Among Children with Pneumococcal Pneumonia and Effusion After 13-Valent Pneumococcal Conjugate Vaccine Introduction in the Dominican Republic.
Ahmed SS; Lessa FC; Coradin H; Sánchez J; Carvalho MDG; Soda E; Peña C; Fernández J; Cedano D; Whitney CG; Feris-Iglesias J
J Infect Dis; 2021 Sep; 224(12 Suppl 2):S228-S236. PubMed ID: 34469563
[TBL] [Abstract][Full Text] [Related]
13. Pneumococcal Conjugated Vaccine Reduces the High Mortality for Community-Acquired Pneumonia in the Elderly: an Italian Regional Experience.
Baldo V; Cocchio S; Gallo T; Furlan P; Romor P; Bertoncello C; Buja A; Baldovin T
PLoS One; 2016; 11(11):e0166637. PubMed ID: 27846277
[TBL] [Abstract][Full Text] [Related]
14. Pneumococcal Conjugate Vaccine Impact on Meningitis and Pneumonia Among Children Aged <5 Years-Zimbabwe, 2010-2016.
Dondo V; Mujuru H; Nathoo K; Jacha V; Tapfumanei O; Chirisa P; Manangazira P; Macharaga J; de Gouveia L; Mwenda JM; Katsande R; Weldegebriel G; Pondo T; Matanock A; Lessa FC
Clin Infect Dis; 2019 Sep; 69(Suppl 2):S72-S80. PubMed ID: 31505631
[TBL] [Abstract][Full Text] [Related]
15. Direct and indirect effects of the 13-valent pneumococcal conjugate vaccine administered to infants and young children.
Esposito S; Principi N;
Future Microbiol; 2015; 10(10):1599-607. PubMed ID: 26439470
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of 13-valent pneumococcal conjugate vaccine on radiological primary end-point pneumonia among cases of severe community acquired pneumonia in children: A prospective multi-site hospital-based test-negative study in Northern India.
Awasthi S; Kohli N; Agarwal M; Pandey CM; Rastogi T; Pandey AK; Roy C; Mishra K; Verma N; Kumar CB; Jain PK; Yadav R; Dhasmana P; Chauhan A; Mohindra N; Shukla RC
PLoS One; 2022; 17(12):e0276911. PubMed ID: 36520841
[TBL] [Abstract][Full Text] [Related]
17. Impact of the 13-valent pneumococcal conjugate vaccine on the incidences of community-acquired pneumonia and pneumonia-related hospitalizations in children ≤5 years after its implementation into the national immunization program of Turkey.
Gönüllü E; Soysal A; Yıldız I; Aydemir G; Tunç T; Karaböcüoğlu M
Hum Vaccin Immunother; 2020 Oct; 16(10):2504-2508. PubMed ID: 32119602
[TBL] [Abstract][Full Text] [Related]
18. Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012.
Farnham AC; Zimmerman CM; Papadouka V; Konty KJ; Zucker JR; Nattanmai GV; Jose S; Rosen JB
JAMA Pediatr; 2015 Jul; 169(7):646-52. PubMed ID: 25938798
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
[TBL] [Abstract][Full Text] [Related]
20. [Effect of the Pneumococcal Conjugated Vaccines on Burden of all Cause Pneumonia, Bacterial Pneumonia and Empyema in Children].
Tsakir C; Özdemir H; Arga G; Konca HK; Çakmak Taşkın E; Öcal D; Çiftçi E; İnce E
Mikrobiyol Bul; 2022 Jul; 56(3):466-479. PubMed ID: 35960238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
